LOOK We have treated hundreds of patients with PAH with long-term intravenous prostacyclin, treprostinil, sildenafil, bosentan, sitaxsentan, ambrisentan, iloprost, and more. We accept referrals from all sources and welcome any interest or questions from health-care workers and from the general public.
LOOK
· A trial of
oral cicletanine to treat PAH is currently enrolling
· A Phase 4 trial of ambrisentan for
patients with PAH is ongoing.
· A trial of a new oral prostacyclin
drug (oral Remodulin) for patients with PAH will begin in 2010.
· A trial adding a new endothelin antagonsist
for patients already on PAH therapy is ongoing.
· Exercise training (rehabilitation) trial:
Click HERE for more info.
· A trial for scleroderma
patients who do not have PAH is ongoing. This study looks at ways to detecte pulmonary
vascular disease in its earliest stages, possibly even before PAH begins
Summary
of Research Trials at Harbor-UCLA
|
Conventional
PULMONARY ARTERIAL
HYPERTENSION TREATMENT
All patients are given an in-depth medical evaluation and counseled on the
risks and benefits of prostacyclin in PAH.
Initiation of prostacyclin takes approximately two days as an inpatient, and
patients are usually ready to return to progressive activities upon discharge.
While patients are hospitalized, their families and/or supporting members will
be instructed on the use of prostacyclin, how to administer the drug, and what
to do in case of an emergency.
For more
information on any of the above trials, call our research coordinator, Joy at
310-222-3560
times